Correlia Biosystems
Next-gen instruments for quantitative protein measurement (We are hiring, check indeed for positions)
Next-gen instruments for quantitative protein measurement (We are hiring, check indeed for positions)
Correlia Biosystems is a biotechnology startup that specializes in developing cutting-edge microscale instruments aimed at expediting the measurement of molecular interactions. Established in 2013 and headquartered in the United States, the company's flagship product, PIXI, enables rapid and precise quantification of biomolecules, offering the ability to address new biological inquiries with just a minuscule sample size of less than two microliters.
The company's innovative approach has attracted substantial investor interest, with the last recorded $9.57M venture round investment led by Cota Capital in October 16, 2020. Correlia Biosystems' prowess in the fields of biotechnology, healthcare, and life sciences reaffirms its strategic positioning in the industry, promising potential for continued growth and innovation.
With a compelling slogan advocating for the recruitment of top talent, it is evident that Correlia Biosystems is focused on expanding its team and furthering its mission. The company's forward-looking approach and sophisticated technology position it as a strong contender in the biotech landscape, with immense potential for disrupting the status quo in quantitative protein measurement.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $9.57M | 1 |
|
16 Oct 2020 |
| Seed | Unknown | - | 04 May 2018 | |
| Seed Round | $120.00K | 2 |
|
04 Jan 2018 |
| Venture Round | Unknown | 1 |
|
01 Dec 2017 |
| Non Equity Assistance | Unknown | 1 | Creative Destruction Lab (CDL) | 08 Oct 2017 |
No recent news or press coverage available for Correlia Biosystems.
We care about your data, and we'd love to use cookies make your experience better.
